Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | USP1 | O94782 | 6/20 | 0.40 |
| ▸ | WDR48 | Q8TAF3 | 2/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22971757 | 0.80 | CHRNB2 (0.51) | CHRM4CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12988214 | 0.79 | CHRNB2 (0.51) | DPP4DPP8DPP9DPP7HRH3 | |
| SCHEMBL17297744 | 0.78 | CHRNB2 (0.54) | DPP4DPP8DPP9DPP7HRH3 | |
| SCHEMBL20756622 | 0.73 | CHRNB2 (0.39) | USP1WDR48CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL23132890 | 0.72 | HRH3 (0.40) | HRH3CHRNB2CHRNA4 | |
| SCHEMBL23108878 | 0.72 | HRH3 (0.40) | HRH3CHRNB2CHRNA4 | |
| SCHEMBL23132893 | 0.72 | HRH3 (0.40) | HRH3CHRNB2CHRNA4 | |
| SCHEMBL23108681 | 0.72 | HRH3 (0.40) | HRH3CHRNB2CHRNA4 | |
| SCHEMBL20756431 | 0.72 | HRH4 (0.38) | HRH3 | |
| SCHEMBL25065331 | 0.72 | HRH3 (0.40) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | DPP4 1075/4885DPP8 610/4885DPP9 715/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | DPP4 1075/4885DPP8 610/4885DPP9 715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.